원료의약품(API) 중간체 시장 규모는 향후 수년간 강력한 성장이 전망됩니다. 2029년에는 연간 평균 성장률(CAGR) 7.5%로 성장할 전망이며, 2,057억 7,000만 달러로 성장이 예측됩니다. 이 예측 기간의 성장 배경에는 개별화 의료에 대한 수요 증가, 신흥 시장으로부터 의약품 수출 증가, 생활습관병 유행, 신규 약물 전달 시스템에 대한 수요 증가, 생물제제 및 바이오시밀러 채용 확대 등이 있습니다. 이 기간에 예상되는 주요 동향으로는 상류 프로세스 및 하류 프로세스의 통합, 파일럿 테스트에 대한 디지털 트윈의 이용, 중간체 합성을 위한 생체 촉매 진보, 스케일업 프로세스에 대한 자동화 도입, 폐기물 절감 기술의 혁신 등이 있습니다.
의약품에 대한 수요가 높아지면 향후 수년간 원료의약품(API) 중간체 시장의 성장을 견인할 것으로 예측됩니다. 의약품은 인간이나 동물의 질병이나 병세를 진단, 치료, 예방, 치유하기 위해 사용되는 물질이나 화합물입니다. 이러한 수요 증가는 주로 장기적인 치료와 일관된 헬스케어 관리를 필요로 하는 만성 질환의 유병률 증가에 의해 촉진되고 있습니다. 원료의약품 중간체는 의약품 유효성분의 효율적인 합성 및 품질 보증을 가능하게 함으로써 의약품 제조에 중요한 역할을 하고 있습니다. 예를 들어 2023년 4월 미국을 거점으로 하는 싱크탱크 미국대서양평의회는 미국이 2022년 중국에서 수입하는 원약은 14억 8,449만 달러 상당으로 2021년 14억 3,708만 달러에서 증가했다고 보고했습니다. 이처럼 의약품 수요의 고조가 원료의약품 중간체 시장의 확대에 크게 기여하고 있습니다.
원료의약품(API) 중간체 시장의 주요 기업은 치료 성적 향상 및 치료 다양화를 위해 소화관 API 중간체와 같은 혁신적인 치료법의 개발을 우선하고 있습니다. 소화기 원료의약품 중간체는 소화기계 질환을 치료하기 위한 원료의약품 제조에 사용되는 필수 화합물입니다. 예를 들어 2023년 10월 중국 제약회사인 후난화등제약은 제약 산업의 높아지는 수요에 대응하기 위해 펙스프라잔 및 보노프라잔의 중간체를 발표했습니다. 이러한 중간체는 적정 제조 기준(GMP) 등급과 비GMP 등급이 모두 있어 산업의 벤치마크를 웃도는 고순도 레벨을 보증하고 있습니다. 연구개발과 상업규모 생산 모두에 유연한 선택지를 제공할 수 있도록 설계된 이 신출시는 의약품 개발에 고품질의 신뢰성 높은 성분을 제공함으로써 혁신적인 소화관 치료에 대한 수요 증가를 지원합니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향 및 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁 및 관세, 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석 및 전략 분석 프레임워크
- 세계의 원료의약품(API) 중간체 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인 및 억제요인)
- 최종 이용 산업의 분석
- 세계의 원료의약품(API) 중간체 시장 : 성장률 분석
- 세계의 원료의약품(API) 중간체 시장 실적 : 규모 및 성장(2019-2024년)
- 세계의 원료의약품(API) 중간체 시장 예측 : 규모 및 성장(2024-2029년, 2034년)
- 세계의 원료의약품(API) 중간체 : 전체 시장 규모(TAM)
제6장 시장 세분화
- 세계의 원료의약품(API) 중간체 시장 : 유형별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 벌크 의약품 중간체
- 화학 중간체
- 세계의 원료의약품(API) 중간체 시장 : 성질 유형별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 식물 유래 중간체
- 동물 유래 중간체
- 미생물 중간체
- 합성 천연물
- 생체변환 중간체
- 세계의 원료의약품(API) 중간체 시장 : 용도별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 진통제
- 항당뇨병제
- 항감염증약
- 심혈관약
- 항암제
- 기타
- 세계의 원료의약품(API) 중간체 시장 : 최종 사용자별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 제약회사
- 연구기관
- 계약 제조 조직
- 기타
- 세계의 원료의약품(API) 중간체 시장 : 벌크 의약품 중간체별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 합성 중간체
- 생명 공학 중간체
- 펩티드 중간체
- 스테로이드 중간체
- 아미노산 중간체
- 세계의 원료의약품(API) 중간체 시장 : 화학 중간체별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 키랄 중간체
- 복소환 중간체
- 유기금속 중간체
- 방향족 중간체
- 지방족 중간체
제7장 지역별 및 국가별 분석
- 세계의 원료의약품(API) 중간체 시장 : 지역별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
- 세계의 원료의약품(API) 중간체 시장 : 국가별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도 및 기업 프로파일
- 원료의약품(API) 중간체 시장 : 경쟁 구도
- 원료의약품(API) 중간체 시장 : 기업 프로파일
- Hetero Labs Ltd.
- Aurobindo Pharma Ltd.
- Ipca Laboratories Ltd.
- Dr. Reddy's Laboratories Ltd.
- Cipla Ltd.
제31장 기타 주요 기업 및 혁신 기업
- Cadila Pharmaceuticals Ltd.
- Lupin Ltd.
- Torrent Pharmaceuticals Ltd.
- Mankind Pharma Ltd.
- Divis Laboratories Ltd.
- Laurus Labs Ltd.
- Jubilant Pharmova Ltd.
- Piramal Pharma Ltd.
- Cambrex Corporation
- Alembic Pharmaceuticals Ltd.
- Granules India Ltd.
- JB Chemicals and Pharmaceuticals Ltd.
- Hovione Holdings SA
- Vasudha Pharma Chem Ltd.
- Concord BIoTech Ltd.
제32장 세계 시장 경쟁 벤치마킹 및 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문 및 전략
- 원료의약품(API) 중간체 시장(2029년) : 새로운 기회를 제공하는 국가
- 원료의약품(API) 중간체 시장(2029년) : 새로운 기회를 제공하는 부문
- 원료의약품(API) 중간체 시장(2029년) : 성장 전략
제36장 부록
AJY
An active pharmaceutical ingredient (API) intermediate is a compound generated during the synthesis of an API, acting as a vital precursor or building block before the final active pharmaceutical ingredient is obtained. It undergoes additional chemical reactions or purification processes to become the finished pharmaceutical product.
API intermediates are primarily categorized into bulk drug intermediates and chemical intermediates. Bulk drug intermediates are chemical substances used as raw materials in the synthesis of APIs. These intermediates can be derived from natural sources-such as plants, animals, or microbes-or classified under synthetic natural products and biotransformed intermediates. They are extensively utilized in the manufacturing of various drugs, including analgesics, antidiabetic agents, anti-infectives, cardiovascular medications, anticancer treatments, and more. The end users of these intermediates include pharmaceutical companies, research institutions, contract manufacturing organizations (CMOs), and other related entities.
The API intermediate market research report is one of a series of new reports from The Business Research Company that cover API intermediate market statistics, including the API intermediate industry's global market size, regional shares, competitors with the API intermediate market share, detailed API intermediate market segments, market trends and opportunities, and any further data you may need to thrive in the API intermediate market. This API intermediate market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The active pharmaceutical ingredient (API) intermediate market size has grown strongly in recent years. It will grow from $142.83 billion in 2024 to $153.97 billion in 2025 at a compound annual growth rate (CAGR) of 7.8%. The growth during the historic period can be attributed to the rising demand for pharmaceutical products, increased adoption of synthetic and biopharmaceutical drugs, growing production of generic medications, enhanced regulatory support and approvals, and heightened investment in pharmaceutical research and development.
The active pharmaceutical ingredient (API) intermediate market size is expected to see strong growth in the next few years. It will grow to $205.77 billion in 2029 at a compound annual growth rate (CAGR) of 7.5%. The projected growth in the forecast period can be attributed to the rising demand for personalized medicine, increasing pharmaceutical exports from emerging markets, growing prevalence of lifestyle-related diseases, heightened demand for novel drug delivery systems, and greater adoption of biologics and biosimilars. Key trends expected during this period include the integration of upstream and downstream processes, use of digital twins for pilot testing, advancements in biocatalysis for intermediate synthesis, incorporation of automation in scale-up processes, and innovations in waste reduction technologies.
The rising demand for pharmaceutical products is expected to drive the growth of the active pharmaceutical ingredient (API) intermediate market in the coming years. Pharmaceutical products are substances or compounds used to diagnose, treat, prevent, or cure diseases and medical conditions in humans or animals. This growing demand is primarily fueled by the increasing prevalence of chronic diseases that require long-term treatment and consistent healthcare management. API intermediates play a crucial role in pharmaceutical manufacturing by enabling the efficient synthesis and quality assurance of active pharmaceutical ingredients. For example, in April 2023, the Atlantic Council of the United States, a U.S.-based think tank, reported that the United States imported $1,484.49 million worth of APIs from China in 2022, up from $1,437.08 million in 2021. Thus, the rising demand for pharmaceutical products is contributing significantly to the expansion of the API intermediate market.
Leading companies in the active pharmaceutical ingredient (API) intermediate market are prioritizing the development of innovative therapies, such as gastrointestinal API intermediates, to improve treatment outcomes and diversify their therapeutic offerings. Gastrointestinal API intermediates are essential chemical compounds used in the production of APIs for treating disorders of the digestive system. For example, in October 2023, Hunan Huateng Pharmaceutical, a China-based pharmaceutical company, introduced Fexuprazan and Vonoprazan intermediates to address the growing needs of the pharmaceutical industry. These intermediates are available in both Good Manufacturing Practice (GMP) and non-GMP grades, ensuring high purity levels that exceed industry benchmarks. Designed to offer flexible options for both research and commercial-scale production, this launch supports the increasing demand for innovative gastrointestinal treatments by providing high-quality, reliable components for drug development.
In March 2024, International Chemical Investors Group (ICIG), a Luxembourg-based chemicals company, acquired Vasant Chemicals Pvt. Ltd. for an undisclosed amount. This acquisition is intended to enhance ICIG's position in the specialty chemicals market by expanding its manufacturing and distribution capabilities, particularly in India and across Asia. Vasant Chemicals Pvt. Ltd., based in India, specializes in the production of active pharmaceutical ingredient (API) intermediates.
Major players in the active pharmaceutical ingredient (api) intermediate market are Hetero Labs Ltd., Aurobindo Pharma Ltd., Ipca Laboratories Ltd., Dr. Reddy's Laboratories Ltd., Cipla Ltd., Cadila Pharmaceuticals Ltd., Lupin Ltd., Torrent Pharmaceuticals Ltd., Mankind Pharma Ltd., Divis Laboratories Ltd., Laurus Labs Ltd., Jubilant Pharmova Ltd., Piramal Pharma Ltd., Cambrex Corporation, Alembic Pharmaceuticals Ltd., Granules India Ltd., JB Chemicals and Pharmaceuticals Ltd., Hovione Holdings S.A., Vasudha Pharma Chem Ltd., Concord Biotech Ltd., ABA Chemicals Private Limited, Clare Laboratories Pvt Ltd., Ind-Swift Laboratories Ltd., Panacea Biotec Ltd., RPG Life Sciences Ltd., Jay Finechem Industries Ltd., Glenmark Life Sciences Ltd., Suven Pharmaceuticals Ltd., IOL Chemicals and Pharmaceuticals Ltd.
North America was the largest region in the active pharmaceutical ingredient (API) intermediate market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in active pharmaceutical ingredient (API) intermediate report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the active pharmaceutical ingredient (API) intermediate market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The active pharmaceutical ingredient (API) intermediate market consists of sales of chiral intermediates, custom intermediates, heterocyclic intermediates, peptide intermediates, and polymer intermediates. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Active Pharmaceutical Ingredient (API) Intermediate Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on active pharmaceutical ingredient (api) intermediate market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for active pharmaceutical ingredient (api) intermediate ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The active pharmaceutical ingredient (api) intermediate market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Type: Bulk Drug Intermediates; Chemical Intermediates
- 2) By Natural: Plant-Derived Intermediates; Animal-Derived Intermediates; Microbial Intermediates; Synthetic Natural Products; Biotransformed Intermediates
- 3) By Application: Analgesics; Antidiabetic Drugs; Anti-Infective Drugs; Cardiovascular Drugs; Anticancer Drugs; Other Applications
- 4) By End-User: Pharmaceutical Companies; Research Institutes; Contract Manufacturing Organizations; Other End-Users
Subsegments
- 1) By Bulk Drug Intermediates: Synthetic Intermediates; Biotech Intermediates; Peptide Intermediates; Steroidal Intermediates; Amino Acid Intermediates
- 2) By Chemical Intermediates: Chiral Intermediates; Heterocyclic Intermediates; Organometallic Intermediates; Aromatic Intermediates; Aliphatic Intermediates
- Companies Mentioned: Hetero Labs Ltd.; Aurobindo Pharma Ltd.; Ipca Laboratories Ltd.; Dr. Reddy's Laboratories Ltd.; Cipla Ltd.
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Active Pharmaceutical Ingredient (API) Intermediate Market Characteristics
3. Active Pharmaceutical Ingredient (API) Intermediate Market Trends And Strategies
4. Active Pharmaceutical Ingredient (API) Intermediate Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Active Pharmaceutical Ingredient (API) Intermediate Growth Analysis And Strategic Analysis Framework
- 5.1. Global Active Pharmaceutical Ingredient (API) Intermediate PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Active Pharmaceutical Ingredient (API) Intermediate Market Growth Rate Analysis
- 5.4. Global Active Pharmaceutical Ingredient (API) Intermediate Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Active Pharmaceutical Ingredient (API) Intermediate Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Active Pharmaceutical Ingredient (API) Intermediate Total Addressable Market (TAM)
6. Active Pharmaceutical Ingredient (API) Intermediate Market Segmentation
- 6.1. Global Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Bulk Drug Intermediates
- Chemical Intermediates
- 6.2. Global Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Natural, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Plant-Derived Intermediates
- Animal-Derived Intermediates
- Microbial Intermediates
- Synthetic Natural Products
- Biotransformed Intermediates
- 6.3. Global Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Analgesics
- Antidiabetic Drugs
- Anti-Infective Drugs
- Cardiovascular Drugs
- Anticancer Drugs
- Other Applications
- 6.4. Global Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Pharmaceutical Companies
- Research Institutes
- Contract Manufacturing Organizations
- Other End-Users
- 6.5. Global Active Pharmaceutical Ingredient (API) Intermediate Market, Sub-Segmentation Of Bulk Drug Intermediates, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Synthetic Intermediates
- Biotech Intermediates
- Peptide Intermediates
- Steroidal Intermediates
- Amino Acid Intermediates
- 6.6. Global Active Pharmaceutical Ingredient (API) Intermediate Market, Sub-Segmentation Of Chemical Intermediates, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Chiral Intermediates
- Heterocyclic Intermediates
- Organometallic Intermediates
- Aromatic Intermediates
- Aliphatic Intermediates
7. Active Pharmaceutical Ingredient (API) Intermediate Market Regional And Country Analysis
- 7.1. Global Active Pharmaceutical Ingredient (API) Intermediate Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Active Pharmaceutical Ingredient (API) Intermediate Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Active Pharmaceutical Ingredient (API) Intermediate Market
- 8.1. Asia-Pacific Active Pharmaceutical Ingredient (API) Intermediate Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Natural, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Active Pharmaceutical Ingredient (API) Intermediate Market
- 9.1. China Active Pharmaceutical Ingredient (API) Intermediate Market Overview
- 9.2. China Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Natural, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Active Pharmaceutical Ingredient (API) Intermediate Market
- 10.1. India Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Natural, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Active Pharmaceutical Ingredient (API) Intermediate Market
- 11.1. Japan Active Pharmaceutical Ingredient (API) Intermediate Market Overview
- 11.2. Japan Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Natural, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Active Pharmaceutical Ingredient (API) Intermediate Market
- 12.1. Australia Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Natural, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Active Pharmaceutical Ingredient (API) Intermediate Market
- 13.1. Indonesia Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Natural, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Active Pharmaceutical Ingredient (API) Intermediate Market
- 14.1. South Korea Active Pharmaceutical Ingredient (API) Intermediate Market Overview
- 14.2. South Korea Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Natural, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Active Pharmaceutical Ingredient (API) Intermediate Market
- 15.1. Western Europe Active Pharmaceutical Ingredient (API) Intermediate Market Overview
- 15.2. Western Europe Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Natural, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Active Pharmaceutical Ingredient (API) Intermediate Market
- 16.1. UK Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Natural, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Active Pharmaceutical Ingredient (API) Intermediate Market
- 17.1. Germany Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Natural, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Active Pharmaceutical Ingredient (API) Intermediate Market
- 18.1. France Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Natural, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Active Pharmaceutical Ingredient (API) Intermediate Market
- 19.1. Italy Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Natural, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Active Pharmaceutical Ingredient (API) Intermediate Market
- 20.1. Spain Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Natural, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Active Pharmaceutical Ingredient (API) Intermediate Market
- 21.1. Eastern Europe Active Pharmaceutical Ingredient (API) Intermediate Market Overview
- 21.2. Eastern Europe Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Natural, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Active Pharmaceutical Ingredient (API) Intermediate Market
- 22.1. Russia Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Natural, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Active Pharmaceutical Ingredient (API) Intermediate Market
- 23.1. North America Active Pharmaceutical Ingredient (API) Intermediate Market Overview
- 23.2. North America Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Natural, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Active Pharmaceutical Ingredient (API) Intermediate Market
- 24.1. USA Active Pharmaceutical Ingredient (API) Intermediate Market Overview
- 24.2. USA Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Natural, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Active Pharmaceutical Ingredient (API) Intermediate Market
- 25.1. Canada Active Pharmaceutical Ingredient (API) Intermediate Market Overview
- 25.2. Canada Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Natural, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Active Pharmaceutical Ingredient (API) Intermediate Market
- 26.1. South America Active Pharmaceutical Ingredient (API) Intermediate Market Overview
- 26.2. South America Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Natural, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Active Pharmaceutical Ingredient (API) Intermediate Market
- 27.1. Brazil Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Natural, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Active Pharmaceutical Ingredient (API) Intermediate Market
- 28.1. Middle East Active Pharmaceutical Ingredient (API) Intermediate Market Overview
- 28.2. Middle East Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Natural, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Active Pharmaceutical Ingredient (API) Intermediate Market
- 29.1. Africa Active Pharmaceutical Ingredient (API) Intermediate Market Overview
- 29.2. Africa Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Natural, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Active Pharmaceutical Ingredient (API) Intermediate Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Active Pharmaceutical Ingredient (API) Intermediate Market Competitive Landscape And Company Profiles
- 30.1. Active Pharmaceutical Ingredient (API) Intermediate Market Competitive Landscape
- 30.2. Active Pharmaceutical Ingredient (API) Intermediate Market Company Profiles
- 30.2.1. Hetero Labs Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Aurobindo Pharma Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Ipca Laboratories Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Dr. Reddy's Laboratories Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Cipla Ltd. Overview, Products and Services, Strategy and Financial Analysis
31. Active Pharmaceutical Ingredient (API) Intermediate Market Other Major And Innovative Companies
- 31.1. Cadila Pharmaceuticals Ltd.
- 31.2. Lupin Ltd.
- 31.3. Torrent Pharmaceuticals Ltd.
- 31.4. Mankind Pharma Ltd.
- 31.5. Divis Laboratories Ltd.
- 31.6. Laurus Labs Ltd.
- 31.7. Jubilant Pharmova Ltd.
- 31.8. Piramal Pharma Ltd.
- 31.9. Cambrex Corporation
- 31.10. Alembic Pharmaceuticals Ltd.
- 31.11. Granules India Ltd.
- 31.12. JB Chemicals and Pharmaceuticals Ltd.
- 31.13. Hovione Holdings S.A.
- 31.14. Vasudha Pharma Chem Ltd.
- 31.15. Concord Biotech Ltd.
32. Global Active Pharmaceutical Ingredient (API) Intermediate Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Active Pharmaceutical Ingredient (API) Intermediate Market
34. Recent Developments In The Active Pharmaceutical Ingredient (API) Intermediate Market
35. Active Pharmaceutical Ingredient (API) Intermediate Market High Potential Countries, Segments and Strategies
- 35.1 Active Pharmaceutical Ingredient (API) Intermediate Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Active Pharmaceutical Ingredient (API) Intermediate Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Active Pharmaceutical Ingredient (API) Intermediate Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
